AZ's Onglyza should highlight heart failure risks, FDA panel advises

AstraZeneca ($AZN) dodged a bullet Tuesday, when an FDA panel of experts almost unanimously backed Onglyza's cardiovascular safety. But the committee did recommend that the label of the diabetes therapy feature information about a potential risk of heart failure. More from FiercePharma